Name Description
sorafenib inhibits tumor cell proliferation and angiogenesis by targeting RAF KINASES and VEGF RECEPTORS; multikinase inhibitor that targets serine/threonine and receptor tyrosine kinases to decrease tumor growth and angiogenesis; FDA approved orphan drug indication for hepatocellular carcinoma in 2006
TCRDv4.6.0
DrugCentral Indication
DrugCentral
sorafenib